Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis
|
|
- Cory Franklin
- 6 years ago
- Views:
Transcription
1 4664 Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis Jennifer Clay Cather, 1 Alison Potts Bleakman, 2 April Naegeli, 2 Jiat Ling Poon, 3 Ashley Wallace, 4 Kristin Hollister, 2 Scott Fretzin 4 1 Modern Dermatology, Dallas, USA; 2 Eli Lilly and Company, Indianapolis, USA; 3 Evidera, Bethesda, USA; 4 Dawes & Fretzin Dermatology Group, Indianapolis, USA This study was sponsored by Eli Lilly and Company.
2 Disclosures J. Cather is in the speaker bureau of: AbbVie, Allergan, Celgene, Janssen, received honoraria from: AbbVie, Eli Lilly and Company, Janssen, Novartis, is a consultant for: AbbVie, Eli Lilly and Company, Janssen, Novartis, is an investigator for: Allergan, Celgene, Cutanea, Dermira, Galderma Labs, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Sandoz, Tolmar Pharma, Vitae, Xenoport, has received grants from: Allergan, Celgene, Cutanea, Dermira, GlaxoSmithKline, Galderma Labs, Janssen, MSD, Novartis, Pfizer, Regeneron, Sandoz, Tolmar Pharma, Vitae, Xenoport, has received other financial benefit from: AbbVie This study was sponsored by Eli Lilly and Company. Medical writing services were provided by Samantha Forster, PhD of ProScribe part of the Envision Pharma Group, and were funded by Eli Lilly and Company
3 Background and Objective Background Surveys of patients with psoriasis suggest that genital involvement occurs in 29%-63% of the population at some point in the course of the disease 1,2 Data from studies that involve physical examination show that 38% of patients have current genital psoriasis involvement 2,3 Patients with genital psoriasis experience greater impairment in health-related quality of life (HRQoL) and sexual health than patients without genital lesions 2,4 Fewer than 50% of patients with genital psoriasis discuss their symptoms with their physician 5 Better understanding of the impact of genital psoriasis is required to improve the treatment and HRQoL of patients Objective To assess the impact of moderate-to-severe genital psoriasis on sexual health and HRQoL 1. Meeuwis KA, et al. Acta Dermatol Venereol. 2011;91: Ryan C, et al. J Am Acad Dermatol. 2015;72: Ji S, et al. Int J Impot Res. 2016;28: Meeuwis KA, et al. Br J Dermatol. 2011;164: Meeuwis KA, et al. Dermatology. 2012;224;
4 Patients and Methods Inclusion Criteria Aged 18 years Physician-diagnosed chronic plaque psoriasis of duration 6 months Involvement of 1% body surface area Past or current genital psoriasis confirmed by dermatologist and self-reported current or recent ( 3 months) moderate-to-severe genital psoriasis (per Patient Global Assessment 4) Response failure or intolerance of 1 topical therapy used for the treatment of genital psoriasis In-depth Patient Interviews One-on-one, semi-structured interviews conducted with patients from 5 US-based clinics Interviews were designed based on literature reviews and clinicians clinical experience of symptom concepts of genital psoriasis that are of greatest clinical relevance to patients Intended to elicit information about genital psoriasis symptoms and their impact on sexual function and HRQoL Patients were given a choice between an in-person interview and a telephone interview Transcripts were coded and analyzed to identify key themes and responses using ATLAS.ti 7.5.9
5 Baseline Demographics and Characteristics Patients (N=20) Age, years 45 (14.2) Sex, n (%) Male 9 (45) Race, n (%) White Other Duration of disease, a years Psoriasis Genital psoriasis Current moderate-to-severe, b n (%) Psoriasis Genital psoriasis a From diagnosis b Self-reported severity of symptoms. Values are mean (standard deviation) unless otherwise stated 18 (90) 2 (5) 18 (14.0) 7.5 (9.7) 18 (90) 19 (95) All patients indicated preference for a telephone interview
6 Impact of Genital Psoriasis on Sexual Activity and Sexual Satisfaction, N=20 Sexual Activity Status a Sexual Satisfaction 10% 45% Active 20% 25% Negatively impacted: Very much 45% Not Active Declined to Answer 30% 25% Quite a bit Not at all Other b a Sexual activity was defined to the patient as not limited to sexual intercourse and inclusive of activities such as masturbation. Interviewer phraseology may have varied b Other includes: Somewhat (10%), A little bit (5%), and Have not had genital psoriasis symptoms in the past week (5%) An equal proportion of patients (45%) reported sexual activity and inactivity Genital psoriasis affected sexual satisfaction either very much or quite a bit in 50% of patients
7 Impact of Genital Psoriasis on Sexual Health Symptom Worsening a Impaired Sexual Experience Reduced Sexual Frequency N=20 patients Impact Reported 80% 80% 80% Avoidance of Sexual Relationships 75% Reduced Sexual Desire 55% Symptom Reported Spontaneous vs. Probed b 60% 65% 35% 60% 10% 20% 15% 45% 15% 45% a Worsening of genital psoriasis symptoms after sexual activity. The presence/absence of each impact was assessed independently of symptom worsening b The interviewer asked probing questions to obtain information regarding specific impacts if not spontaneously mentioned Individual sexual impacts were reported by the majority of patients interviewed Most (90%) spontaneously reported 1 impact of genital psoriasis on sexual health
8 Representative Patient Quotes: Impacts on Sexual Health if there s patches on the penis itself and you get a full erection, then the skin can tear, so you have to limit [sexual activity] to when that s not the case So sometimes you make a calculated decision as to how badly do I want to engage in this activity given what the cost is going to be and pain and discomfort post activity for hours and/or days if his stuff gets on there, it sets it [my skin] on fire, so you just have to immediately sit in another Epsom salt bath it s just like three days of hell, so it s not worth it to me it s taken it [sexual desire] away just because it s just too painful I told him if it comes between having sex because it s so painful and not being married, then I choose not to be married Selected quotes are from different patients and have been edited to minimize repetitive language
9 Impact of Genital Psoriasis on HRQoL N=20 patients Impact Reported Negative Impact on: Symptom Reported Spontaneously vs. Probed a Mood/Emotion Physical Activities Daily Activities 95% 70% 60% Social/Leisure Activities 45% Relationships with Friends & Family 45% Work/School 35% 25% 10% 10% 10% 20% 5% 70% 60% 50% 35% 25% 30% a The interviewer asked probing questions to obtain information regarding specific impacts if not spontaneously mentioned The majority of patients expressed HRQoL impacts on mood/emotion (95%), physical activities (70%), and daily activities (60%) Patients were more likely to report impacts on HRQoL after probing, rather than spontaneously
10 Representative Patient Quotes: Impacts on HRQoL it s affected my life in so many ways What I can wear, what activities I can involve myself in I don t really like to do a whole lot because I am feeling discomfort with the stress, and a lack of confidence whether it be with my partner or just in every day life I m not social any more. I don t get out much. I ve become a recluse if it starts itching or something, it s not seemly that you would, be able to take care of yourself in a public situation running and jogging is something I really I ve had to take [time] off work because I just couldn t stand it even your pants that you don t think are tight are still tight enjoy when that process of cracking and the skin is peeling off you can t jog or run Selected quotes are from different patients and have been edited to minimize repetitive language
11 Conclusions Nearly all patients reported at least one negative impact on sexual aspects of their quality of life Genital psoriasis was reported to negatively impact patients general well-being, affecting personal relationships and physical, social, and daily activities Patients spontaneously reported sexual health impacts more frequently than they reported general HRQoL impacts Dermatologists are encouraged to discuss the impact of genital psoriasis with patients, as they may disclose more information when asked
12 Supplementary Information
13 Interview Guide: Sexual Health 1. Are you sexually active? 2. Have your genital psoriasis symptoms affected your sexual life? a a. How do your genital psoriasis symptoms affect your sexual desire? b. How do your genital psoriasis symptoms physically affect your sexual experience? I. How do genital psoriasis symptoms affect your sexual frequency? II. Do your genital psoriasis symptoms worsen during/following intercourse? a III. Does your genital psoriasis cause you to avoid having sexual relationships? If so, why? Do you avoid sexual relationships due to the: Appearance of your genital psoriasis symptoms? Pain experienced during intercourse? Discomfort experienced during intercourse? Worsening of your genital psoriasis symptoms during intercourse? Way your genital psoriasis makes you feel? a Questions followed by If so, in what way(s)?
14 Interview Guide: Overall HRQoL Impact 1. How have your genital psoriasis symptoms affected your life in general? Note: Spontaneously reported symptoms were noted first without any probing 2. Which of these symptoms affects your life the most? How? 3. Have your genital psoriasis symptoms affected your physical activities? a 4. Have your genital psoriasis symptoms affected your mood or emotional status? a 5. Have your genital psoriasis symptoms affected your social or leisure activities? a 6. Have your genital psoriasis symptoms affected your work (or school)? a 7. Have your genital psoriasis symptoms affected your daily activities? a 8. Have your relationships with friends or family been affected? a a Questions followed by If so, in what way(s)?
The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health
Dermatol Ther (Heidelb) (2018) 8:33 44 https://doi.org/10.1007/s13555-017-0212-3 ORIGINAL RESEARCH The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact
More informationPatients Perspectives on the Impact of Genital Psoriasis: A Qualitative Study
Dermatol Ther (Heidelb) (2017) 7:447 461 DOI 10.1007/s13555-017-0204-3 ORIGINAL RESEARCH Patients Perspectives on the Impact of Genital Psoriasis: A Qualitative Study Jennifer Clay Cather. Caitriona Ryan.
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationSymptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission
Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission 93 Korman, NJ 1, Zhao, Y 2, Roberts, J 3 Pike, J 3, Lu, J 2, Tran, MH 2 (Please see
More informationPsoriasis Disease Severity Affects Patient Satisfaction With Therapy
82 Psoriasis Disease Severity Affects Patient Satisfaction With Therapy Korman NJ 1, Zhao Y 2, Tran MH 2, Lu J 2 (Please see authors affiliations on the last panel) Background Psoriasis is a chronic, immune
More informationInitiation and evaluation of the effect of biologic treatment. ActaDV ActaDV
CLINICAL REPORT 1 Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab Jeanette Halskou HESSELVIG, Alexander EGEBERG,
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationPremature Ejaculation
Premature Ejaculation Patient Information Urology Department Author ID: PH Leaflet Number: Urol 014 Version: 4 Name of Leaflet: Premature Ejaculation Date Produced: November 2016 Review Date: November
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.13216 JEADV SHORT REPORT HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVE At the conclusion of this activity, participants should be better able to: Answer common patient questions about the course of atopic dermatitis (AD) and effective strategies for treating
More informationAbstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
More informationExpanded Prostate Cancer Index Composite for Clinical Practice (EPIC - CP) Pilot results
Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC - CP) Pilot results Outline 1. EPIC-CP Background 2. EPIC-CP Pilots - Phase I and II 3. EPIC Pilot Phase II Results 2 EPIC-CP Background
More informationCost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis
1108 Cost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis Steven R. Feldman, MD, PhD 1 ; Tom Tencer, PhD 2 ; Zoe Clancy, PharmD,
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationTo order reprints or e-prints of JDD articles please contact JDD
June 2017 534 VOLUME 16 ISSUE 6 Copyright 2017 ORIGINAL ARTICLE Journal of Drugs in Dermatology The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris Lauren K. Hoffman
More informationThe Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement
The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement Julie Jefferson 1, Racheal Manhart 2, Jill Moore 3 Richard Scher 4, Phoebe Rich 5 1Dermatology,
More informationContinuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
DOI: 1.1111/jdv.14163 JEADV ORIGINAL ARTICLE Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis A. Blauvelt, 1, * K.A.Papp, 2 H. Sofen,
More informationMark G. Lebwohl 1 Arthur Kavanaugh
Am J Clin Dermatol (2016) 17:87 97 DOI 10.1007/s40257-015-0169-x ORIGINAL RESEARCH ARTICLE US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the
More informationDoes the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?
DOI: 10.1111/jdv.15226 JEADV ORIGINAL ARTICLE Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? A. Langenbruch,* M.A. Radtke, M. Gutknecht,
More informationGOOD IN BED SURVEYS. Report #3. Orgasm
GOOD IN BED SURVEYS KEY FINDINGS Report #3 Orgasm Although men experienced orgasm more frequently than women, the pleasure and enjoyment experienced by men and women was equally high, with the majority
More informationHEY CHARLES, I TOOK YOUR ADVICE AND WENT FOR MC! GREAT, BUT HERE is SOME IMPORTANT info YOU NEED TO REMEMBER! TAKE HOME BOOKLET
HEY CHARLES, I TOOK YOUR ADVICE AND WENT FOR MC! GREAT, BUT HERE is SOME IMPORTANT info YOU NEED TO REMEMBER! TAKE HOME BOOKLET You ve made an important choice to go for MC. There are two important issues
More informationGlenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant Thaçi, MD, a Andrew Blauvelt, MD, MBA, b Kristian
More informationTreatment Changes in PaMents with Moderate-to- Severe Psoriasis: A RetrospecMve Chart Review
Treatment Changes in PaMents with Moderate-to- Severe Psoriasis: A RetrospecMve Chart Review 4052 Jaclyn A. Smith 1, BS, Brooke Wehausen 1, BS, Irma Richardson 1, MHA, Yang Zhao 4, PhD, Yunfeng Li 4, PhD,
More informationActive tasks (eg, chores, exercise, swimming, lifting) activities) Choice of clothes (eg, color) Annoyance/anger. Psychological impact.
How Do Breast Pain and Breakthrough Bleeding Associated With Hormonal Treatments for Menopausal Symptoms Impact Postmenopausal Women s Lives: Qualitative Interviews With Postmenopausal Women in the USA,
More informationTranslating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment
Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment This symposium took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 1.1111/jdv.14878 JEADV ORIGINAL ARTICLE Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-tosevere psoriasis through 5 years of treatment (SCULPTURE
More informationSex Talk for Self-Advocates #3 Safe Sex Practices - Sexually Transmitted Infections (STIs)
Sex Talk for Self-Advocates #3 Safe Sex Practices - Sexually Transmitted Infections (STIs) Self-Advocacy Educator - Max Barrows Sex Educator - Katherine McLaughlin www.elevatustraining.com Sex Educator
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationOhio PREP Region 7 Data Report. Prepared by: Ohio University s Voinovich School of Leadership and Public Affairs January 2018
Ohio PREP Region 7 Data Report Prepared by: Ohio University s Voinovich School of Leadership and Public Affairs January 2018 Introduction This report provides data from 2013 through July 2017 for Ohio
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationSource: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California
Source: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California OVERVIEW Steven R. Feldman, MD, PhD, and Alan Menter, MD, as well as principal investigators,
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 10.1111/jdv.13990 JEADV ORIGINAL ARTICLE Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis
More informationHealth Care Professional Questionnaire
Methodology An online survey, titled Let's Talk About Sexual Health Warts and All, was fielded from February 25 March 28, 2016 by HealthyWomen, in partnership with PharmaDerm, a division of Fougera Pharmaceuticals
More informationPatient reported outcomes in chronic skin diseases: ehealth applications for clinical practice van Cranenburgh, O.D.
UvA-DARE (Digital Academic Repository) Patient reported outcomes in chronic skin diseases: ehealth applications for clinical practice van Cranenburgh, O.D. Link to publication Citation for published version
More informationKirklees Museums & Galleries. Volunteer + Culture = Wellbeing?
Kirklees Museums & Galleries Volunteer + Culture = Wellbeing? Context Why? Reduction in funding H&W and Economic Resilience Early Intervention & Prevention Communities doing more for themselves Intelligenceled
More informationSEXUALITY AND DIABETES
SEXUALITY AND DIABETES Sexuality is one of the greatest gifts we have as humans. When it works it can be wonderful and when it doesn t work it can be confusing and tremendously frustrating. WHAT DOES DIABETES
More informationDaily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment
Accepted Manuscript Daily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment Michael H. Gold, MD, FAAD, Mark Lebwohl,
More informationWHI Form 55 Estrogen-Alone Survey Ver. 2
Date Received: - - (M/D/Y) Reviewed By: - Affix label here- Clinical Center/ID: - - First Name M.I. Last Name Contact Type: Phone Visit Type: Form Administration: Mail Semi-Annual # Self 3 Visit 3 Annual
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More informationClient Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS
Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Before using medications to transition and feminize, you need to know the possible advantages, disadvantages and risks
More informationDenial and Unawareness in Huntington s Disease
Denial and Unawareness in Huntington s Disease Arik Johnson, PsyD HDSA Center of Excellence at UCLA June 21, 2014 30 th Annual HDSA Convention Dallas, TX Disclaimer The information provided by speakers
More informationIL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future
IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future This symposium took place on 13 th September 2018, as part of the 27 th European Academy of Dermatology and Venereology (EADV) Congress
More informationHealing Trauma Evaluation Year 1 Findings
2551 Galena Avenue #1774 Simi Valley, CA 93065 310-801-8996 Envisioning Justice Solutions, Inc. Determining the Programs, Policies, and Services Needed to Rebuild the Lives of Criminal Justice Involved
More informationOhio PREP Region 7: Cuyahoga County Board of Health October 2017 through September 2018 Data Report
Ohio PREP Region 7: Cuyahoga County Board of Health October 2017 through September 2018 Data Report Provided by Ohio University s Voinovich School of Leadership and Public Affairs 1 P age This report covers
More informationEmerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis These posters were presented at the 5 th World Psoriasis & Psoriatic Arthritis Conference 2018, held from 27 th 30 th June in Stockholm,
More informationDo misery and happiness both love company? The emotional consequences of listening to experiences shared by others.
Pursuit - The Journal of Undergraduate Research at the University of Tennessee Volume 6 Issue 1 Article 23 April 2015 Do misery and happiness both love company? The emotional consequences of listening
More informationMaking Connections: Early Detection Hearing and Intervention through the Medical Home Model Podcast Series
Making Connections: Early Detection Hearing and Intervention through the Medical Home Model Podcast Series Podcast 2 Utilization of the Teach-Back Methodology in Early Hearing Detection and Intervention
More informationProtecting Your Health: Understanding and Preventing STDs
Protecting Your Health: Understanding and Preventing STDs A Lesson Plan from Rights, Respect, Responsibility: A K-12 Curriculum Fostering responsibility by respecting young people s rights to honest sexuality
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationHaving Sex. Some people are heterosexual. Fact Sheet
Fact Sheet Having Sex Sometimes people who are in a close relationship and like each other a lot, or love each other, like to kiss and cuddle. Sometimes they show how much they like or love each other
More informationCalcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Am J Clin Dermatol (17) 18:5 411 DOI.7/s257-17-258- ORIGINAL RESEARCH ARTICLE Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis
More informationThe transition from independent living to residential care is a significant life event for many older adults
Sense of Belonging in the Transition to Residential Aged Care Matthew Condie and Rob Ranzijn University of South Australia National Conference of the Australian Association of Gerontology, Sydney NSW Nov
More informationStroke Impact Scale VERSION 3.0
Stroke Impact Scale VERSION 3.0 The purpose of this questionnaire is to evaluate how stroke has impacted your health and life. We want to know from YOUR POINT OF VIEW how stroke has affected you. We will
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationAYPH conference Young peoples experiences of skin conditions Tess McPherson Consultant dermatologist Oxford
Skin, Stigma, Services & Support AYPH conference Young peoples experiences of skin conditions Tess McPherson Consultant dermatologist Oxford Skin Skin problems major problem in young people Skin condition
More informationFROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT
FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT This symposium took place on 15 th September 2017 as a part of the 26th European Academy of Dermatology and Venereology
More informationLet s Talk About Clinical Trials: A Discussion Guide for Patients
Let s Talk About Clinical Trials: A Discussion Guide for Patients Participating in a clinical trial helps researchers studying Crohn s disease and ulcerative colitis answer important questions about the
More informationTHINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
More informationFind your ED cure End your frustration. Renew your confidence. Feel complete. Take the next steps. Erectile dysfunction and heart disease
Take the next steps Visit your general practitioner or cardiologist to learn more about your risk for cardiovascular disease. Visit EDCure.org to: Take the online ED quiz and get your customized treatment
More informationINSOMNIA SEVERITY INDEX
Name: Date: INSOMNIA SEVERITY INDEX For each of the items below, please circle the number that most closely corresponds to how you feel. 1. Please rate the CURRENT (i.e. last 2 weeks) severity of your
More informationDiabetes and You. A Quick Guide
Diabetes and You A Quick Guide Contents Introduction to Diabetes What is Diabetes? 03... What is diabetes Diabetes is a condition where there is 05... What does this mean for me? too much glucose (a type
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Most people with psoriasis or rosacea are not being treated: a large population study Permalink https://escholarship.org/uc/item/4nc3p4q2 Journal Dermatology Online
More informationMOR106, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study
, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study Diamant Thaçi 1, Maria Magdalena Constantin 2, Bernadette Rojkovich 3, Helen Timmis 4,
More informationInternational Index of Erectile Function Questionnaire IIEF
International Index of Erectile Function Questionnaire IIEF Instructions: These questions ask about the effects your erections have had on your sex life, over the past 4 weeks. Please answer the following
More informationSexual Feelings. Having sexual feelings is not a choice, but what you do with your feelings is a choice. Let s take a look at this poster.
Sexual Feelings It may be your first instinct to deny that your child will ever have sexual feelings. You may even do everything in your power to suppress those feelings if they do surface. You won t succeed
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /bjd.
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory The Harvard community has made
More informationPublic Attitudes and Knowledge about HIV/AIDS in Georgia Kaiser Family Foundation
Public Attitudes and Knowledge about HIV/AIDS in Georgia Kaiser Family Foundation Chart Pack November 2015 Methodology Public Attitudes and Knowledge about HIV/AIDS in Georgia is a representative, statewide
More informationWe believe that young people are all one step away from making a life changing difference for themselves, and each other.
Mental Health Background about the Youth Action Group We are a group of emerging young leaders (ages 18 25) who are passionate about raising the profile of young people in Melbourne. Our group, the YAG
More informationTeen Sexual Health Survey
Instructions Teen Sexual Health Survey Thank you for taking part in our survey. DO NOT write your name on this survey. The answers you give will be kept private. No one will know what you write. Answer
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationPatterns of social, psychological and spiritual decline towards the end of life in lung cancer and heart failure
Patterns of social, psychological and spiritual decline towards the end of life in lung cancer and heart failure APCC 2007 Scott A Murray, Marilyn Kendall, Elizabeth Grant, Kirsty Boyd, Aziz Sheikh, Stephen
More informationElizabeth Ann Golden, PA-C
Elizabeth Ann Golden, PA-C Dawes Fretzin Clinical Research Group, LLC Dawes Fretzin Dermatology Group, LLC 8103 Clearvista Parkway, Suite 260 8103 Clearvista Parkway, Suite 220 Indianapolis, Indiana 46256
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationSelf-harm Workshop. Gemma Fieldsend
Self-harm Workshop Gemma Fieldsend Don t give up you are not alone it s important to not feel alone Self-harm Self-harm is a common coping mechanism for young people who turn to it as quickly as other
More informationTop tips for engaging children and young people of different ages
Top tips for engaging children and young people of different ages Dr Zoe Marshman z.marshman@sheffield.ac.uk @zmarshman Outline Benefits of involving children and young people in developing patient information
More informationPresented by: Adelaide A Hebert, MD UTHealth McGovern Medical School, Houston, TX
Evaluation of the Efficacy, Safety and Tolerability of 4% Once-Daily in Subjects with Moderate to Severe Acne Vulgaris Treated Topically for Up to 52 Weeks A Hebert, J Del Rosso, M Rico, R Woolson, E de
More informationThe symptom recognition and help- seeking experiences of men in Australia with testicular cancer: A qualitative study
The symptom recognition and help- seeking experiences of men in Australia with testicular cancer: A qualitative study Stephen Carbone,, Susan Burney, Fiona Newton & Gordon A. Walker Monash University gordon.walker@med.monash.edu.au
More informationSexual Concerns. Mental Health Topics
Sexual Concerns A lot of people have concerns about their sex life. Common concerns and problems that affect one or both sex partners Talk to your partner about your include: sexual concerns. n Little
More informationAge / Sex: 31-year-old bi-racial male admitted to hospital through. Background:
Stephen M. Goldfinger, MD Chart Review: The Patient You Hate to Treat PATIENT INFO 31 / Male Age / Sex: 31-year-old bi-racial male admitted to hospital through Background: Psychiatric Emergency Services.
More informationMoving beyond the big talk
Moving beyond the big talk Strategies for engaging children of all ages in discussions about sexual health April 11, 2016 Monica Faulkner, PhD, LMSW Research Professor, School of Social Work Co-Director,
More information